Pseudohypoglycemia refers to the experience of typical low blood sugar symptoms (like confusion, palpitations, or disorientation) despite having normal or above-normal plasma glucose levels (above 70 mg/dL or >3.9 mmol/L). Historically, the term also described discrepancies between actual and measured glucose levels.
Clinical pseudohypoglycemia occurs when individuals, often with psychological or personality disorders, report symptom relief after eating, though their glucose levels remain within normal ranges. These symptoms are frequently linked to psychosomatic issues, emotional instability, or sleep disturbances.
Recognizing pseudohypoglycemia is crucial for clinicians to avoid unnecessary tests or overtreatment.
Epidemiology
Exact prevalence is unknown, but pseudohypoglycemia is more commonly identified in:
Patients with peripheral vascular disorders, hematologic conditions, or critical illness.
Individuals undergoing hospital-based glucose monitoring, where lab errors or technical limitations may falsely lower glucose readings.
Certain populations such as neonates (due to high hematocrit) or individuals with hyperviscosity syndromes and hypertriglyceridemia.
Anatomy
Pathophysiology
Etiology
Pseudohypoglycemia can arise from several physiological and artifactual mechanisms. One major cause is impaired capillary flow, which leads to reduced glucose transport and increased tissue extraction of glucose. This is commonly seen in conditions such as Raynaud’s phenomenon, acrocyanosis, peripheral vascular disease, Eisenmenger syndrome, and circulatory shock. Another significant factor is in vitro glucose consumption, which occurs due to delayed processing of blood samples. This phenomenon is particularly notable in cases of leukocytosis, leukemia, leukemoid reactions, polycythemia vera, chronic hemolytic anemia, and other primary red cell disorders. Additionally, African trypanosomiasis can cause parasite-driven glucose consumption in vitro. Hyperviscosity syndromes such as Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance (MGUS) may also lead to artifactual hypoglycemia. Moreover, certain metabolic and technical interferences can contribute to falsely low glucose readings. These include hypertriglyceridemia, and the use of drugs like high-dose ascorbic acid, dopamine, acetaminophen, and mannitol.
Genetics
Prognostic Factors
Favorable outcomes are expected if the underlying cause of pseudohypoglycemia is recognized and corrected.
Poor prognostic indicators include:
Unrecognized pseudohypoglycemia, leading to unnecessary treatment with glucose and inappropriate investigations.
Critical illness (e.g., circulatory shock or organ dysfunction) that may confound diagnosis and require intensive monitoring.
Delayed sample processing, particularly in patients with hematologic malignancies, can lead to significant misinterpretation unless handled promptly.
Clinical History
Age Group:
All age groups can be affected, but the elderly and critically ill patients may be more susceptible due to higher likelihood of comorbidities or lab interference. Neonates are particularly prone due to high hematocrit levels affecting glucose meter accuracy.
Physical Examination
pseudohypoglycemia is an artifact of measurement, physical findings are often disproportionate to the degree of glucose abnormality reported. Clinical correlation and confirmatory testing (e.g., venous plasma glucose, repeated sampling with prompt processing) are essential.
Age group
Associated comorbidity
Psychological or somatic symptom disorders
Critical illness with circulatory shock or oxygen therapy
Use of specific medications (e.g., high-dose ascorbic acid, acetaminophen)
Delayed sample processing in hospital settings
Associated activity
Acuity of presentation
Mild or subacute in most cases with vague symptoms
Occasionally acute when neuroglycopenic symptoms appear, such as confusion, slurred speech, or seizures
Potential for misdiagnosis as true hypoglycemia, prompting unnecessary and urgent interventions unless properly correlated clinically using Whipple’s triad
High oxygen therapy (affecting glucose oxidase meters)
Psychogenic Causes
Anxiety or panic attacks
Somatic symptom disorder
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Pseudohypoglycemia is not true hypoglycemia, so treatment focuses on identifying and addressing the underlying cause rather than administering glucose.
Non-pharmacological management of pseudohypoglycemia focuses on accurate diagnosis, physiological correction, lifestyle regulation, and patient reassurance. Accurate glucose measurement is essential—venous plasma glucose should be used instead of capillary readings to confirm hypoglycemia. Laboratory staff should be instructed to process blood samples promptly and either refrigerate them or use fluoride-containing tubes to prevent glycolysis. In cases involving high oxygen therapy, high hematocrit (such as in neonates), or acid-base disturbances, glucose dehydrogenase-based meters should be used to avoid false readings. Physiological factors contributing to pseudohypoglycemia should be addressed by improving peripheral circulation—keeping extremities warm in patients with Raynaud’s phenomenon or acrocyanosis, avoiding cold exposure, optimizing vascular health in peripheral vascular disease or Eisenmenger syndrome, and ensuring adequate hydration to reduce blood viscosity in hyperviscosity syndromes.
Administration of a pharmaceutical agent
Pseudohypoglycemia is an artifactual or perception-based condition, not true biochemical hypoglycemia. Therefore, routine use of pharmaceutical agents is generally not required. However, in specific cases where pseudohypoglycemia is secondary to an underlying pathological condition, targeted pharmacological interventions may be warranted to treat the root cause.
While pseudohypoglycemia does not require direct glucose-correcting interventions, certain interventional procedures may be necessary when the underlying cause is a treatable pathological condition that distorts glucose readings. These procedures aim to correct sample-related artifacts or systemic contributors, rather than to treat pseudohypoglycemia itself.
use-of-phases-in-managing-pseudohypoglycemia
Pseudohypoglycemia management involves five key phases. First, in the Recognition Phase, symptoms of hypoglycemia are noted despite normal glucose levels, often in patients with conditions like Raynaud’s or leukemia. The Confirmation Phase ensures accurate glucose measurement using venous samples and proper handling, while ruling out meter-related errors. In the Evaluation Phase, clinicians investigate underlying medical or psychological causes. The Intervention Phase focuses on treating root issues (e.g., plasmapheresis for hyperviscosity, stopping interfering drugs) and improving lab practices. Lastly, the Reassurance and Education Phase involves informing patients about the benign nature of the condition and avoiding unnecessary treatments or anxiety.
Pseudohypoglycemia refers to the experience of typical low blood sugar symptoms (like confusion, palpitations, or disorientation) despite having normal or above-normal plasma glucose levels (above 70 mg/dL or >3.9 mmol/L). Historically, the term also described discrepancies between actual and measured glucose levels.
Clinical pseudohypoglycemia occurs when individuals, often with psychological or personality disorders, report symptom relief after eating, though their glucose levels remain within normal ranges. These symptoms are frequently linked to psychosomatic issues, emotional instability, or sleep disturbances.
Recognizing pseudohypoglycemia is crucial for clinicians to avoid unnecessary tests or overtreatment.
Exact prevalence is unknown, but pseudohypoglycemia is more commonly identified in:
Patients with peripheral vascular disorders, hematologic conditions, or critical illness.
Individuals undergoing hospital-based glucose monitoring, where lab errors or technical limitations may falsely lower glucose readings.
Certain populations such as neonates (due to high hematocrit) or individuals with hyperviscosity syndromes and hypertriglyceridemia.
Pseudohypoglycemia can arise from several physiological and artifactual mechanisms. One major cause is impaired capillary flow, which leads to reduced glucose transport and increased tissue extraction of glucose. This is commonly seen in conditions such as Raynaud’s phenomenon, acrocyanosis, peripheral vascular disease, Eisenmenger syndrome, and circulatory shock. Another significant factor is in vitro glucose consumption, which occurs due to delayed processing of blood samples. This phenomenon is particularly notable in cases of leukocytosis, leukemia, leukemoid reactions, polycythemia vera, chronic hemolytic anemia, and other primary red cell disorders. Additionally, African trypanosomiasis can cause parasite-driven glucose consumption in vitro. Hyperviscosity syndromes such as Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance (MGUS) may also lead to artifactual hypoglycemia. Moreover, certain metabolic and technical interferences can contribute to falsely low glucose readings. These include hypertriglyceridemia, and the use of drugs like high-dose ascorbic acid, dopamine, acetaminophen, and mannitol.
Favorable outcomes are expected if the underlying cause of pseudohypoglycemia is recognized and corrected.
Poor prognostic indicators include:
Unrecognized pseudohypoglycemia, leading to unnecessary treatment with glucose and inappropriate investigations.
Critical illness (e.g., circulatory shock or organ dysfunction) that may confound diagnosis and require intensive monitoring.
Delayed sample processing, particularly in patients with hematologic malignancies, can lead to significant misinterpretation unless handled promptly.
Age Group:
All age groups can be affected, but the elderly and critically ill patients may be more susceptible due to higher likelihood of comorbidities or lab interference. Neonates are particularly prone due to high hematocrit levels affecting glucose meter accuracy.
pseudohypoglycemia is an artifact of measurement, physical findings are often disproportionate to the degree of glucose abnormality reported. Clinical correlation and confirmatory testing (e.g., venous plasma glucose, repeated sampling with prompt processing) are essential.
Psychological or somatic symptom disorders
Critical illness with circulatory shock or oxygen therapy
Use of specific medications (e.g., high-dose ascorbic acid, acetaminophen)
Delayed sample processing in hospital settings
Mild or subacute in most cases with vague symptoms
Occasionally acute when neuroglycopenic symptoms appear, such as confusion, slurred speech, or seizures
Potential for misdiagnosis as true hypoglycemia, prompting unnecessary and urgent interventions unless properly correlated clinically using Whipple’s triad
High oxygen therapy (affecting glucose oxidase meters)
Psychogenic Causes
Anxiety or panic attacks
Somatic symptom disorder
Pseudohypoglycemia is not true hypoglycemia, so treatment focuses on identifying and addressing the underlying cause rather than administering glucose.
Endocrinology, Reproductive/Infertility
Non-pharmacological management of pseudohypoglycemia focuses on accurate diagnosis, physiological correction, lifestyle regulation, and patient reassurance. Accurate glucose measurement is essential—venous plasma glucose should be used instead of capillary readings to confirm hypoglycemia. Laboratory staff should be instructed to process blood samples promptly and either refrigerate them or use fluoride-containing tubes to prevent glycolysis. In cases involving high oxygen therapy, high hematocrit (such as in neonates), or acid-base disturbances, glucose dehydrogenase-based meters should be used to avoid false readings. Physiological factors contributing to pseudohypoglycemia should be addressed by improving peripheral circulation—keeping extremities warm in patients with Raynaud’s phenomenon or acrocyanosis, avoiding cold exposure, optimizing vascular health in peripheral vascular disease or Eisenmenger syndrome, and ensuring adequate hydration to reduce blood viscosity in hyperviscosity syndromes.
Pseudohypoglycemia is an artifactual or perception-based condition, not true biochemical hypoglycemia. Therefore, routine use of pharmaceutical agents is generally not required. However, in specific cases where pseudohypoglycemia is secondary to an underlying pathological condition, targeted pharmacological interventions may be warranted to treat the root cause.
Endocrinology, Reproductive/Infertility
While pseudohypoglycemia does not require direct glucose-correcting interventions, certain interventional procedures may be necessary when the underlying cause is a treatable pathological condition that distorts glucose readings. These procedures aim to correct sample-related artifacts or systemic contributors, rather than to treat pseudohypoglycemia itself.
Endocrinology, Reproductive/Infertility
Pseudohypoglycemia management involves five key phases. First, in the Recognition Phase, symptoms of hypoglycemia are noted despite normal glucose levels, often in patients with conditions like Raynaud’s or leukemia. The Confirmation Phase ensures accurate glucose measurement using venous samples and proper handling, while ruling out meter-related errors. In the Evaluation Phase, clinicians investigate underlying medical or psychological causes. The Intervention Phase focuses on treating root issues (e.g., plasmapheresis for hyperviscosity, stopping interfering drugs) and improving lab practices. Lastly, the Reassurance and Education Phase involves informing patients about the benign nature of the condition and avoiding unnecessary treatments or anxiety.
Pseudohypoglycemia refers to the experience of typical low blood sugar symptoms (like confusion, palpitations, or disorientation) despite having normal or above-normal plasma glucose levels (above 70 mg/dL or >3.9 mmol/L). Historically, the term also described discrepancies between actual and measured glucose levels.
Clinical pseudohypoglycemia occurs when individuals, often with psychological or personality disorders, report symptom relief after eating, though their glucose levels remain within normal ranges. These symptoms are frequently linked to psychosomatic issues, emotional instability, or sleep disturbances.
Recognizing pseudohypoglycemia is crucial for clinicians to avoid unnecessary tests or overtreatment.
Exact prevalence is unknown, but pseudohypoglycemia is more commonly identified in:
Patients with peripheral vascular disorders, hematologic conditions, or critical illness.
Individuals undergoing hospital-based glucose monitoring, where lab errors or technical limitations may falsely lower glucose readings.
Certain populations such as neonates (due to high hematocrit) or individuals with hyperviscosity syndromes and hypertriglyceridemia.
Pseudohypoglycemia can arise from several physiological and artifactual mechanisms. One major cause is impaired capillary flow, which leads to reduced glucose transport and increased tissue extraction of glucose. This is commonly seen in conditions such as Raynaud’s phenomenon, acrocyanosis, peripheral vascular disease, Eisenmenger syndrome, and circulatory shock. Another significant factor is in vitro glucose consumption, which occurs due to delayed processing of blood samples. This phenomenon is particularly notable in cases of leukocytosis, leukemia, leukemoid reactions, polycythemia vera, chronic hemolytic anemia, and other primary red cell disorders. Additionally, African trypanosomiasis can cause parasite-driven glucose consumption in vitro. Hyperviscosity syndromes such as Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance (MGUS) may also lead to artifactual hypoglycemia. Moreover, certain metabolic and technical interferences can contribute to falsely low glucose readings. These include hypertriglyceridemia, and the use of drugs like high-dose ascorbic acid, dopamine, acetaminophen, and mannitol.
Favorable outcomes are expected if the underlying cause of pseudohypoglycemia is recognized and corrected.
Poor prognostic indicators include:
Unrecognized pseudohypoglycemia, leading to unnecessary treatment with glucose and inappropriate investigations.
Critical illness (e.g., circulatory shock or organ dysfunction) that may confound diagnosis and require intensive monitoring.
Delayed sample processing, particularly in patients with hematologic malignancies, can lead to significant misinterpretation unless handled promptly.
Age Group:
All age groups can be affected, but the elderly and critically ill patients may be more susceptible due to higher likelihood of comorbidities or lab interference. Neonates are particularly prone due to high hematocrit levels affecting glucose meter accuracy.
pseudohypoglycemia is an artifact of measurement, physical findings are often disproportionate to the degree of glucose abnormality reported. Clinical correlation and confirmatory testing (e.g., venous plasma glucose, repeated sampling with prompt processing) are essential.
Psychological or somatic symptom disorders
Critical illness with circulatory shock or oxygen therapy
Use of specific medications (e.g., high-dose ascorbic acid, acetaminophen)
Delayed sample processing in hospital settings
Mild or subacute in most cases with vague symptoms
Occasionally acute when neuroglycopenic symptoms appear, such as confusion, slurred speech, or seizures
Potential for misdiagnosis as true hypoglycemia, prompting unnecessary and urgent interventions unless properly correlated clinically using Whipple’s triad
High oxygen therapy (affecting glucose oxidase meters)
Psychogenic Causes
Anxiety or panic attacks
Somatic symptom disorder
Pseudohypoglycemia is not true hypoglycemia, so treatment focuses on identifying and addressing the underlying cause rather than administering glucose.
Endocrinology, Reproductive/Infertility
Non-pharmacological management of pseudohypoglycemia focuses on accurate diagnosis, physiological correction, lifestyle regulation, and patient reassurance. Accurate glucose measurement is essential—venous plasma glucose should be used instead of capillary readings to confirm hypoglycemia. Laboratory staff should be instructed to process blood samples promptly and either refrigerate them or use fluoride-containing tubes to prevent glycolysis. In cases involving high oxygen therapy, high hematocrit (such as in neonates), or acid-base disturbances, glucose dehydrogenase-based meters should be used to avoid false readings. Physiological factors contributing to pseudohypoglycemia should be addressed by improving peripheral circulation—keeping extremities warm in patients with Raynaud’s phenomenon or acrocyanosis, avoiding cold exposure, optimizing vascular health in peripheral vascular disease or Eisenmenger syndrome, and ensuring adequate hydration to reduce blood viscosity in hyperviscosity syndromes.
Pseudohypoglycemia is an artifactual or perception-based condition, not true biochemical hypoglycemia. Therefore, routine use of pharmaceutical agents is generally not required. However, in specific cases where pseudohypoglycemia is secondary to an underlying pathological condition, targeted pharmacological interventions may be warranted to treat the root cause.
Endocrinology, Reproductive/Infertility
While pseudohypoglycemia does not require direct glucose-correcting interventions, certain interventional procedures may be necessary when the underlying cause is a treatable pathological condition that distorts glucose readings. These procedures aim to correct sample-related artifacts or systemic contributors, rather than to treat pseudohypoglycemia itself.
Endocrinology, Reproductive/Infertility
Pseudohypoglycemia management involves five key phases. First, in the Recognition Phase, symptoms of hypoglycemia are noted despite normal glucose levels, often in patients with conditions like Raynaud’s or leukemia. The Confirmation Phase ensures accurate glucose measurement using venous samples and proper handling, while ruling out meter-related errors. In the Evaluation Phase, clinicians investigate underlying medical or psychological causes. The Intervention Phase focuses on treating root issues (e.g., plasmapheresis for hyperviscosity, stopping interfering drugs) and improving lab practices. Lastly, the Reassurance and Education Phase involves informing patients about the benign nature of the condition and avoiding unnecessary treatments or anxiety.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
